Travere Therapeutics (NASDAQ: TVTX) reported Q4 EPS of $0.94, $2.12 better than the analyst estimate of ($1.18). Revenue for the quarter came in at $45.05 million versus the consensus estimate of $41.68 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.